LErafAON

LErafAON is a liposome-encapsulated antisense oligodeoxynucleotide designed to target the mRNA of human c-Raf (RAF1), a serine/threonine-protein kinase that acts as a regulatory link between Ras GTPases and the MAPK/ERK signaling cascade. By binding to the translation initiation site of c-Raf mRNA, LErafAON blocks its expression and production, thereby inhibiting Raf-mediated cell proliferation and survival pathways. This mechanism is intended to enhance the cytotoxic effects of radiation and chemotherapy in various solid tumors, including those resistant to standard treatments. Developed by NeoPharm, clinical development reached Phase 1/2 for advanced cancers but was ultimately discontinued[1][2][4][5][7].

Other names

liposomal c-raf antisense oligonucleotide